Daria Olena Berger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Daria Olena Berger has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
- Jürg Barben
Paediatric Pulmonology & CF Centre, Children's Hospital of Eastern Switzerland, St. Gallen, Switzerland
2 shared publications Alastair Reid
1 shared publicationAndrea Holubova
1 shared publication- Ann-Katrin Kraeuter
Laboratory of Psychiatric Neuroscience, Australian Institute of Tropical Health and Medicine, James Cook University, Townsville, QLD, Australia
1 shared publication Anna Cardillo
1 shared publicationAnna Tamanini
1 shared publication
Latest Publications
- 23 April 2024
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (4) , 796-803
Cystic fibrosis newborn screening in Switzerland – evaluation and scenarios for improvement after 11 years of follow-up
- 23 April 2024
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (4) , 796-803
Cystic fibrosis newborn screening in Switzerland – evaluation and scenarios for improvement after 11 years of follow-up
- 10 November 2022
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 22 (3) , 484-495
European survey of newborn bloodspot screening for CF: opportunity to address challenges and improve performance
- 10 November 2022
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 22 (3) , 484-495
European survey of newborn bloodspot screening for CF: opportunity to address challenges and improve performance
- Open Access
External Validation of the Predicting Asthma Risk in Children (PARC) tool in a clinical cohort
Rationale: The Predicting Asthma Risk in Children (PARC) tool uses questionnaire-based respiratory symptoms collected from preschool children to predict their risk of asthma 5 years later. The tool was originally developed and externally validated in population-based settings and has not yet been validated in a clinical setting. Objective: To externally validate the PARC tool in children seen in paediatric pulmonology clinics. Methods: The Swiss Paediatric Airway Cohort (SPAC) is a prospective study of children seen in respiratory outpatient clinics across Switzerland. This analysis included children seen at ages 1-6 years for cough or wheeze at baseline and who completed the follow-up questionnaire 2 years later. The outcome was defined as current wheeze plus use of asthma medication. In sensitivity analyses, we explored effects of varied inclusion criteria and outcomes. We assessed performance by describing sensitivity, specificity, negative and positive predictive value (NPV, PPV), area under the curve (AUC), scaled Brier’s score and Nagelkerke’s R 2 scores and compared performance in SPAC to that achieved in the original population, the Leicester Respiratory Cohort (LRC). Results: Among the 346 children included, 125 (36%) reported the outcome after 2 years. At a PARC score cut-off of 4, sensitivity was higher (95% vs 79%) but specificity lower (14% vs 57%) in SPAC compared to LRC. NPV was comparable (0.84 vs. 0.87) as was PPV (0.37 vs.0.42). Discrimination was lower in SPAC (AUC of 0.71 vs 0.78), as were Nagelkerke’s R 2 (0.18 vs 0.28) and scaled Brier’s scores (0.13 vs 0.22). When the outcome was changed to moderately severe asthma (>4 attacks plus use of asthma medication), there were improvements in AUC (0.74), sensitivity (0.97), specificity (0.22) and NPV (0.99), but some deterioration in PPV (0.13), R 2 (0.15) and scaled Brier score (0.09). Conclusion: While the PARC tool performs well in a population-based setting and has some clinical utility, in particular for ruling out the development of asthma, this study highlights the need for new prognostic prediction tools to be developed specifically for the clinical setting. Funding: SNSF:320030_182628, SLA2019-03_641670
Open AccessExternal Validation of the Predicting Asthma Risk in Children (PARC) tool in a clinical cohort
Rationale: The Predicting Asthma Risk in Children (PARC) tool uses questionnaire-based respiratory symptoms collected from preschool children to predict their risk of asthma 5 years later. The tool was originally developed and externally validated in population-based settings and has not yet been validated in a clinical setting. Objective: To externally validate the PARC tool in children seen in paediatric pulmonology clinics. Methods: The Swiss Paediatric Airway Cohort (SPAC) is a prospective study of children seen in respiratory outpatient clinics across Switzerland. This analysis included children seen at ages 1-6 years for cough or wheeze at baseline and who completed the follow-up questionnaire 2 years later. The outcome was defined as current wheeze plus use of asthma medication. In sensitivity analyses, we explored effects of varied inclusion criteria and outcomes. We assessed performance by describing sensitivity, specificity, negative and positive predictive value (NPV, PPV), area under the curve (AUC), scaled Brier’s score and Nagelkerke’s R 2 scores and compared performance in SPAC to that achieved in the original population, the Leicester Respiratory Cohort (LRC). Results: Among the 346 children included, 125 (36%) reported the outcome after 2 years. At a PARC score cut-off of 4, sensitivity was higher (95% vs 79%) but specificity lower (14% vs 57%) in SPAC compared to LRC. NPV was comparable (0.84 vs. 0.87) as was PPV (0.37 vs.0.42). Discrimination was lower in SPAC (AUC of 0.71 vs 0.78), as were Nagelkerke’s R 2 (0.18 vs 0.28) and scaled Brier’s scores (0.13 vs 0.22). When the outcome was changed to moderately severe asthma (>4 attacks plus use of asthma medication), there were improvements in AUC (0.74), sensitivity (0.97), specificity (0.22) and NPV (0.99), but some deterioration in PPV (0.13), R 2 (0.15) and scaled Brier score (0.09). Conclusion: While the PARC tool performs well in a population-based setting and has some clinical utility, in particular for ruling out the development of asthma, this study highlights the need for new prognostic prediction tools to be developed specifically for the clinical setting. Funding: SNSF:320030_182628, SLA2019-03_641670
- 1 September 2016
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 68, 157-166
Cortisol awakening response in patients with psychosis: Systematic review and meta-analysis
- 1 September 2016
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 68, 157-166
Cortisol awakening response in patients with psychosis: Systematic review and meta-analysis